NCT07649304

AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-10-09Est. Completion: 2028-04-30

Enrollment target: 15 participants

Other microbiome trials you might be interested in

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasPhase 1Recruiting

AIDS-Related LymphomaAnn Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma

This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, predniso…

La Jolla, United StatesEst. completion Oct 10, 2024

View Trial →

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV InfectionPhase 2Completed

Lymphoma, AIDS-relatedLymphoma, Large B-Cell, Diffuse

Background: * Human immunodeficiency virus (HIV)-infected patients have a weakened immune system, and chemotherapy, whi…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.